Slan Medicinal Holdings and group companies are part of a network of independent associated companies focused on improving patient health and addressing unmet medical needs by acquiring, developing, manufacturing and commercializing specialty pharmaceutical products in niche orphan disease and specialty market segments.
Mr. Burke serves as the controlling shareholder and/or Chairman of the Board of Eolas Pharma Teoranta, West Therapeutic Development, LLC, Buckeye Pharmaceuticals, LLC and Orphan Pharmacy Services, LLC.
Prior to founding MMB Healthcare Investments, Mr. Burke was one of three founding investors and an operating executive at Marathon Pharmaceuticals, LLC, a specialty pharmaceutical company that acquired, developed, grew and then divested specialty and orphan disease pharmaceutical products.
Prior to Marathon, Mr. Burke was one of the first members of the Ovation Pharmaceuticals’ executive team. As an operating executive he focused on sales, marketing, business development and the assessment of acquisition targets. In 2008, he was named one of the “45 under 45 Emerging Pharma Leaders” by Pharmaceutical Executive. He became chief commercial officer of Lundbeck Inc. following Lundbeck’s acquisition of Ovation in 2009.
Prior to Ovation, Mr. Burke spent eight years in the Pharmaceuticals Products Division at Abbott Laboratories, where he served in various sales and marketing roles and managed specialty market and primary care product lines.
Mr. Burke holds a B.A. from Providence College and an M.B.A. from the Kellogg School of Management at Northwestern University.
Mr. Wiener is the founder, President and Chief Executive Officer of Orphan Pharmacy Services, LLC (OPS). Marc and his team of experienced pharmacy executives are building a high touch patient focused specialty pharmacy serving the needs of patients with orphan diseases.
Prior to founding OPS, Mr. Wiener was the co-founder and CEO of Linden Care from 2009-2016. The majority of Linden Care was sold to private equity firm, BelHealth Investment Partners, in 2013.
Prior to co-founding Linden Care, Mr. Wiener founded Vitality Pharmaceutical Services in 1992, a provider of specialty pharmacy services in the New York Metro area. Vitality was sold to MIM Corp (BioScrip) in 2002.
Mr. Wiener graduated from St. John’s University in 1989 with a degree in Pharmacy.
Mr. Lopez is the Director of Pharmacy Services of Orphan Pharmacy Services, LLC. His responsibilities include oversight of the Pharmacy Department, ensuring compliance with all State and Federal pharmacy rules and regulations.
Mr. Lopez came to Orphan Pharmacy Services, LLC. in June 2017 from a national specialty pharmacy where he served as the Supervising Pharmacist since 2015. He previously held supervisory positions in varied pharmacy settings including chain, independent, hospital, long term, care, specialty including compounding, hospice, and pain management.
Mr. Lopez received his pharmacy training from Saint John’s University where he earned his BS in Pharmacy in 1995. Mr. Lopez currently holds pharmacist licensure in 25 States and continually expands his licensure holdings.
Mr. Kelly is the founding Director and General Manager of Eolas Pharma Teoranta and is responsible for all EMEA based operations of the associated companies. Mr. Kelly has over 20 years of experience in pharmaceutical industry.
Prior to his roles at Eolas Pharma Teoranta, Mr. Kelly was an operating executive and General Manager of Bioniche Pharma Group Limited, the injectable generic pharmaceuticals subsidiary of Bioniche Life Sciences, Inc. ("BLSI", TSX: BNC) from 1992 – 2006 when it was acquired by private equity firm RoundTable Healthcare Partners. Mr. Kelly remained with Bioniche as General Manager of Irish operations through a period of rapid sales growth of $ 7 MM annual turnover in 2006 to $130 MM annual turnover in 2010. The company was sold to Mylan Inc. (NASDAQ: MYL) in 2010 for $550 MM in cash. Following the sale, Mr. Kelly became the CFO of Mylan Institutional based in Chicago, IL through 2013 after which he returned to Galway Ireland and joined Chanelle Group, a private Animal and Human Health pharmaceutical company.
Damien received a Bachelor of Science degree from the National University of Ireland, Galway and an MBA from the Open University of Ireland.
Mr. Reinfelds serves as the General Counsel and V.P. of Legal Affairs of the MMB Healthcare network of independent associated healthcare companies. In this role he manages mergers and acquisitions and corporate legal matters. Mr. Reinfelds executed the group’s first acquisition, Cosyntropin Depot, and follow-on acquisitions and transactions providing the basis for formation of the group EMEA companies.
Prior to his role with the MMB Healthcare network of independent associated healthcare companies, Mr. Reinfelds was counsel for Marathon Pharmaceuticals, LLC from 2014 to 2017. Prior to his role at Marathon, he was with Lundbeck LLC prior to 2014 and with Ovation Pharmaceuticals, Inc. from 2008 until its acquisition by Lundbeck in 2009.
Mr. Reinfelds earned his J.D. from The John Marshall Law School and his Ph.D in Biology from Illinois Institute of Technology. He is a member of the Illinois bar and is licensed to practice before the United States Patent and Trademark Office as a registered patent attorney.
Mr. Burke serves as an Executive Board Member of the MMB Healthcare network of independent associated healthcare companies. In this role he provides insight and counsel on mergers and acquisitions as well as directing corporate financing strategy for the various companies.
Tom Burke is an accomplished finance executive with over 25 years of experience in the real estate, principal investment, private equity, fixed income and investment banking sectors, primarily with Lehman Brothers, Dresdner Kleinwort and Wachovia Securities International, with the last 16 years in London and the prior 10 years in New York.
Tom has successfully operated in both principal and advisory roles in multiple international jurisdictions. He has completed equity and debt transactions in the real estate; mortgage; infrastructure; sports and media; asset backed operating company sectors raising, financing or investing more than $15 billion in over 50 transactions.
Tom received a BA from Georgetown University in 1988 and an MBA in finance from Columbia University in 1993.
Dr. Heifets is the Chief Medical Officer of West Therapeutic Development, LLC. His responsibilities include oversight of pharmacovigilance for investigational and marketed products, medical affairs, clinical development and medical information services.
Dr. Heifets came to West in January of 2018 from Abbvie, Inc., where he served as Therapeutic Area Lead for Nephrology Global Medical Affairs since 2012. He previously led global teams in nephrology at BMS and Hoffman LaRoche (2006-2012).
Prior to his career in pharmaceutical industry, Dr. Heifets spent 20 years in clinical and academic positions and has led Kidney transplant teams and fellowship program at Temple University Hospital and Hahnemann University Hospital in Philadelphia.
Dr. Heifets received his Nephrology training at Washington University in St. Louis (Barnes Hospital), residency at University of Wisconsin (Milwaukee Clinical Campus - Mt. Sinai). He received his M.D. in 1978 from The First Moscow Medical Institute (Sechenov), USSR.